Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,434 shares of the medical research company’s stock after selling 412 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Charles River Laboratories International were worth $339,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. VisionPoint Advisory Group LLC lifted its stake in Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 74 shares during the period. Covestor Ltd lifted its stake in Charles River Laboratories International by 100.0% during the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 87 shares during the period. Headlands Technologies LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter valued at approximately $37,000. Operose Advisors LLC purchased a new position in shares of Charles River Laboratories International during the 3rd quarter valued at approximately $42,000. Finally, Salem Investment Counselors Inc. increased its holdings in shares of Charles River Laboratories International by 65.5% during the 2nd quarter. Salem Investment Counselors Inc. now owns 240 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 95 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at $3,437,635. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at $626,155.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,932 shares of company stock worth $3,693,663. Company insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CRL shares. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. UBS Group boosted their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Argus boosted their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Robert W. Baird boosted their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Trading Down 1.1 %

NYSE CRL opened at $229.90 on Thursday. The firm’s 50-day moving average is $253.47 and its two-hundred day moving average is $220.92. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The stock has a market capitalization of $11.84 billion, a P/E ratio of 24.96, a PEG ratio of 1.85 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. During the same period in the prior year, the firm earned $2.98 earnings per share. The business’s revenue for the quarter was down 7.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).